These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26717378)

  • 1. Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists.
    Liabeuf S; Scaltieux LM; Masmoudi K; Roussel B; Moragny J; Andrejak M; Gras-Champel V
    Medicine (Baltimore); 2015 Dec; 94(52):e2366. PubMed ID: 26717378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptation and validation of an adverse drug reaction preventability score for bleeding due to vitamin K antagonists.
    Liabeuf S; Masmoudi K; Scailteux LM; Moragny J; Masson H; Brnet-Dufour V; Andrejak M; Gras-Champel V
    Medicine (Baltimore); 2016 Sep; 95(39):e4762. PubMed ID: 27684801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.
    van Rein N; Lijfering WM; Bos MH; Herruer MH; Vermaas HW; van der Meer FJ; Reitsma PH
    PLoS One; 2016; 11(12):e0164485. PubMed ID: 27935941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.
    Pastori D; Lip GYH; Farcomeni A; Del Sole F; Sciacqua A; Perticone F; Marcucci R; Grifoni E; Pignatelli P; Violi F;
    Int J Cardiol; 2018 Aug; 264():58-63. PubMed ID: 29776574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice.
    Desmettre T; Dehours E; Samama CM; Jhundoo S; Pujeau F; Guillaudin C; Hecquart C; Clerson P; Crave JC; Jaussaud R
    Crit Care; 2012 Oct; 16(5):R185. PubMed ID: 23036234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors of vitamin K antagonist overcoagulation.
    Marie I; Leprince P; Menard JF; Tharasse C; Levesque H
    QJM; 2012 Jan; 105(1):53-62. PubMed ID: 21880698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study.
    Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM
    Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [INTERNATIONAL NORMALIZED RATIO VALUES AND HEMORRHAGE IN HOSPITALIZED PATIENTS STARTING WARFARIN THERPY: AN OBSERVATIONAL STUDY].
    Abadi U; Ellis MH
    Harefuah; 2015 Aug; 154(8):490-3, 541-2. PubMed ID: 26480611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries.
    Cotté FE; Benhaddi H; Duprat-Lomon I; Doble A; Marchant N; Letierce A; Huguet M
    Clin Ther; 2014 Sep; 36(9):1160-8. PubMed ID: 25151574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
    Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK;
    PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients.
    Karrowni W; Wang TY; Chen AY; Thomas L; Saucedo JF; El Accaoui RN
    Heart; 2015 Feb; 101(4):264-70. PubMed ID: 25336230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment.
    Gorzelak-Pabiś P; Zyzak S; Krewko Ł; Broncel M
    Pol Arch Med Wewn; 2016 Aug; 126(7-8):494-501. PubMed ID: 27511466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Over-anticoagulation by vitamin K antagonists and gender differences.
    Barcellona D; Schirru P; Mameli A; Cornacchini S; Fenu L; Marongiu F
    Int J Cardiol; 2022 Sep; 362():147-151. PubMed ID: 35533748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.
    Becattini C; Franco L; Beyer-Westendorf J; Masotti L; Nitti C; Vanni S; Manina G; Cattinelli S; Cappelli R; Sbrojavacca R; Pomero F; Marten S; Agnelli G
    Int J Cardiol; 2017 Jan; 227():261-266. PubMed ID: 27843050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin K antagonists and emergencies.
    Lapostolle F; Siguret V; Martin AC; Pailleret C; Vigué B; Zerbib Y; Tazarourte K
    Eur J Emerg Med; 2018 Dec; 25(6):378-386. PubMed ID: 29462053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.